Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Denali Therapeutics Inc.DNLI · Entity 1735 | Director · President and CEO | August 12, 2026 | August 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Denali Therapeutics Inc.
Report date August 12, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,120,384 |
Reported balance
After 2026-08-12 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-12 · Gift · Disposed 32,220 · Balance 2,120,384 F1: Reflects an in-kind charitable contribution of 32,220 shares of DNLI to a donor advised fund. F2: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. |
| Common StockSEC Table I · non-derivative | Direct | 296,833 |
Reported balance
Holding disclosure · report date 2026-08-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 296,833 F3: Includes 184,915 unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an in-kind charitable contribution of 32,220 shares of DNLI to a donor advised fund.
F2: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
F3: Includes 184,915 unvested RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 02, 2019 Filed Apr 3, 2019 23:02 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,200 | $24.52 | $78,464.00 |
DisclosureSEC source: 0001209191-19-023478 · doc4.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,606,721 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $23.87 to $24.86 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:02 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 6,050 | $23.91 | $144,655.50 |
DisclosureSEC source: 0001209191-19-023478 · doc4.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,609,921 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $23.35 to $24.19 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| March 05, 2019 Filed Mar 5, 2019 23:18 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 6,141 | $21.97 | $134,917.77 |
DisclosureSEC source: 0001209191-19-016931 · doc4.xml · nonDerivative · entry 6 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,615,971 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $21.42 to $22.32 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 23:18 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,700 | $22.83 | $38,811.00 |
DisclosureSEC source: 0001209191-19-016931 · doc4.xml · nonDerivative · entry 5 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,622,112 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $22.61 to $23.17 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 23:18 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 4,442 | $21.87 | $97,146.54 |
DisclosureSEC source: 0001209191-19-016931 · doc4.xml · nonDerivative · entry 4 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,623,812 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $21.54 to $22.28 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:18 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,050 | $22.91 | $46,965.50 |
DisclosureSEC source: 0001209191-19-016931 · doc4.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,628,254 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $22.82 to $23.03 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:18 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 4,000 | $22.19 | $88,760.00 |
DisclosureSEC source: 0001209191-19-016931 · doc4.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,630,304 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $21.76 to $22.75 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 22:54 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 281,600 | $0.00 Strike: $18.13 | $0.00 |
DisclosureSEC source: 0001209191-19-009061 · doc4.xml · derivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,600 Underlying: Common Stock · 281,600 shares Expires 2029-02-07 F4 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 8, 2020, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 22:54 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantRestricted Stock Units · Derivative | 35,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-009061 · doc4.xml · derivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,200 Underlying: Common Stock · 35,200 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: 25% of the restricted stock units shall vest on February 8, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F3 · derivative.expiration_date: 25% of the restricted stock units shall vest on February 8, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 22:54 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantRestricted Stock Units · Derivative | 11,031 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-009061 · doc4.xml · derivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,031 Underlying: Common Stock · 11,031 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: 50% of the restricted stock units shall vest on February 8, 2020 and the remaining 50% of the restricted stock units shall vest on February 8, 2021, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · derivative.expiration_date: 50% of the restricted stock units shall vest on February 8, 2020 and the remaining 50% of the restricted stock units shall vest on February 8, 2021, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| February 05, 2019 Filed Feb 5, 2019 23:27 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 8,230 | $18.83 | $154,970.90 |
DisclosureSEC source: 0001209191-19-007483 · doc4.xml · nonDerivative · entry 5 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,634,304 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.55 to $19.29 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| February 04, 2019 Filed Feb 5, 2019 23:27 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 854 | $19.12 | $16,328.48 |
DisclosureSEC source: 0001209191-19-007483 · doc4.xml · nonDerivative · entry 4 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,642,534 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.04 to $19.23 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| February 04, 2019 Filed Feb 5, 2019 23:27 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,200 | $18.49 | $59,168.00 |
DisclosureSEC source: 0001209191-19-007483 · doc4.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,643,388 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.00 to $18.95 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 23:27 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 6,050 | $18.65 | $112,832.50 |
DisclosureSEC source: 0001209191-19-007483 · doc4.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,646,588 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.40 to $18.97 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2019 Filed Jan 4, 2019 23:52 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 4,933 | $20.02 | $98,758.66 |
DisclosureSEC source: 0001209191-19-002284 · doc4.xml · nonDerivative · entry 6 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,652,638 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.75 to $20.31 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2019 Filed Jan 4, 2019 23:52 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,300 | $19.18 | $24,934.00 |
DisclosureSEC source: 0001209191-19-002284 · doc4.xml · nonDerivative · entry 5 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,657,571 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.72 to $19.68 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 23:52 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 6,050 | $18.89 | $114,284.50 |
DisclosureSEC source: 0001209191-19-002284 · doc4.xml · nonDerivative · entry 4 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,658,871 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.56 to $19.42 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 23:52 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,000 | $20.24 | $20,240.00 |
DisclosureSEC source: 0001209191-19-002284 · doc4.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,664,921 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $20.09 to $20.44 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 23:52 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 5,050 | $19.42 | $98,071.00 |
DisclosureSEC source: 0001209191-19-002284 · doc4.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,665,921 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.04 to $19.99 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 22:06 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 400 | $19.16 | $7,664.00 |
DisclosureSEC source: 0001209191-18-061329 · doc4.xml · nonDerivative · entry 4 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,670,971 F3 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.15 to $19.17 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 22:06 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 17,933 | $18.42 | $330,273.85 |
DisclosureSEC source: 0001209191-18-061329 · doc4.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,671,371 F3 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.05 to $18.86 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| November 27, 2018 Filed Dec 6, 2018 22:06 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GiftCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-061329 · doc4.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,689,304 F1 · kind: The shares were disposed of in connection with a bona fide gift by the Reporting Person to a donor advised fund. F2 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| November 15, 2018 Filed Nov 15, 2018 23:13 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 13,588 | $18.12 | $246,236.30 |
DisclosureSEC source: 0001209191-18-058797 · doc4.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,729,304 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.00 to $18.49 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| November 13, 2018 Filed Nov 15, 2018 23:13 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 4,746 | $18.00 | $85,428.00 |
DisclosureSEC source: 0001209191-18-058797 · doc4.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,742,892 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 22:01 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 18,333 | $21.72 | $398,192.76 |
DisclosureSEC source: 0001209191-18-054056 · doc4.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,747,638 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $21.36 to $22.22 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 21:25 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 18,333 | $19.06 | $349,426.98 |
DisclosureSEC source: 0001209191-18-049906 · doc4.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,765,971 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.65 to $19.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:41 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 18,334 | $18.05 | $330,928.70 |
DisclosureSEC source: 0001209191-18-049118 · doc4.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,784,304 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.00 to $18.20 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| February 26, 2018 Filed Mar 1, 2018 00:53 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $22.16 | $0.00 |
DisclosureSEC source: 0001209191-18-014727 · doc4.xml · derivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2028-02-25 F2 · derivative.exercise_date: 25% of the shares subject to the option will vest on February 26, 2019 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| December 13, 2017 Filed Mar 1, 2018 00:53 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 5 | $20.47 | $102.35 |
DisclosureSEC source: 0001209191-18-014727 · doc4.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,505 Read SEC document |
| December 12, 2017 Filed Dec 12, 2017 22:34 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries B-1 Preferred Stock · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-065240 · doc4.xml · derivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: The Series B-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: The Series B-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. Read SEC document |
| December 12, 2017 Filed Dec 12, 2017 22:34 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-065240 · doc4.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series B-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.